BBSRC Portfolio Analyser
Award details
Novel prodrug strategies mediated by the tyrosinase enzyme for the treatment of melanoma
Reference
SBD07534
Principal Investigator / Supervisor
Professor Helen Osborn
Co-Investigators /
Co-Supervisors
Institution
University of Reading
Department
Chemistry
Funding type
Research
Value (£)
85,262
Status
Completed
Type
Research Grant
Start date
04/08/1997
End date
04/08/1999
Duration
24 months
Abstract
The proposed research will address the problems associated with conventional treatment of melanoma by developing a novel prodrug strategy for the selective delivery of anti-cancer compounds to melanoma. The tyrosinase enzyme is uniquely located within melanosomes suggesting the viability of a prodrug delivery system triggered by this enzyme. Carbohydrate derivatives which have been rationally designed to display key structured features known to optimise their anti-cancer properties will be prepared and incorporated into novel tyrosine-derived prodrugs. The selectivity of action of these prodrugs on melanogenic cells compared to non- melanogenic cells `in vitro' will be investigated.
Summary
unavailable
Committee
Closed Committee - Biomolecular Sciences (BMS)
Research Topics
X – not assigned to a current Research Topic
Research Priority
X – Research Priority information not available
Research Initiative
Structural biology and design applications (SBD) [1996]
Funding Scheme
X – not Funded via a specific Funding Scheme
I accept the
terms and conditions of use
(opens in new window)
export PDF file
back to list
new search